Researchers at he University of Texas have published a series of cannabinoid receptor 2 (CB2) agonists for the treatment of neuropathic pain.
Filed under: gpcr | Tagged: agonist, Cannabinoid, Cannabinoid CB2, CB2, Preclinical, Research, Univ Texas | Leave a Comment »
Evotec AG have announced the initiation of a Phase I clinical trial of a small molecule VR1 (vanilloid receptor 1) antagonist in collaboration with Pfizer
Filed under: Uncategorized | Tagged: antagonist, Evotec, Pfizer, phase I, TRPV1, Vanilloid, vanilloid 1 | Leave a Comment »
Alexza has initiated a second Phase III trial of AZ-004 (Staccato, loxapine) for the treatment of acute agitation in patients with schizophrenia or bipolar disorder.
Filed under: gpcr | Tagged: 5-HT2, 5HT2, antagonist, AZ-004, AZ004, D2, Dopamine, Dopamine D2, loxapine, Staccato | Leave a Comment »
Titan Pharmaceuticals have announced positive, statistically significant results from its phase III clinical trial of Probuphine in the treatment of opioid addiction.
Filed under: gpcr | Tagged: agonist, antagonist, kappa opioid, Opioid, Opioid kappa, Opioid mu, phase III, Titan | Leave a Comment »
Chelsea Therapeutics has received approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to begin a Phase II trial of Droxidopa, alone and in combination with carbidopa, for the treatment of Fibromyalgia.
Filed under: gpcr | Tagged: Dainippon Sumitomo, Chelsea Therapeutics, Droxidopa, norepinephrine | Leave a Comment »
